<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210524051384N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-25</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Tranexamic Acid in bleeding during burn surgery</public_title>
      <acronym>TXA</acronym>
      <scientific_title>Evaluation of the effect of intravenous tranexamic acid on bleeding during burn surgery: a double blinded clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>82</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66298</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, in order to allocate patients to intervention and control groups, a randomization method limited by the block randomization method will be used. Blocking is usually used to balance the number of samples assigned to each of the studied groups. This feature helps the researcher to equal the number of samples assigned to each of the studied groups in cases where intermediate analysis is required during the sampling process. In this study, by equal to the size of blocks, blocks with size 6 (three participants in the intervention group and three participants in the control group) will be used, Blinding description: Patients who have entry criteria and do not have non-entry criteria will be included in the study after obtaining informed consent. The file number and specifications of each patient will be recorded in predetermined forms. Then, according to the file number and using computer software, they enter one of the two groups of α and β group. This division is carried out by the statistician and the results are provided to the medical records officer of the operating room in closed envelopes. Then, based on the file number in each envelope and the clinical trial code allocated, that person will be a candidate for Tranexamic Acid or standard treatment. The surgeon (responsible for the implementation of burn surgery), the operating room assistant (responsible for recording patient information in predetermined lists), the head of the medical records unit of the operating room, the patient, the anesthesiologist, and the anesthesiologist are not informed of the contents of the envelope and the type of treatment of each patient.</study_design>
      <phase>4</phase>
      <hc_freetext>Burn Injury.</hc_freetext>
      <i_freetext>Intervention 1: Severe burn patients with good hemodynamic status enter the operating room and undergo anesthesia. In the β group (receiving 10mg/kg tranexamic acid infusion before surgery) before induction of anesthesia, 10mg/kg of tranexamic acid solution in normal saline serum will be infused for 5 minutes. Then, the patient will be anesthetized under the supervision of an anesthesiologist. Then, from the onset of surgery to the end of the surgery, 1mg/kg of the same substance will be infused into the serum every hour. Hemodynamic status and bleeding rate are calculated. Necessary support is induced for the hemodynamic balance of patients. At the same time, drug and placebo infusion continues during surgery. At the end of the surgery, the mentioned items are set up by an anesthesiologist and burn specialist in a questionnaire and the patient is transferred to recovery. In the recovery section, a blood sample is taken to measure the amount of hemoglobin, hematocrit, and coagulation profile. Intervention 2: Control group: Severe burn patients with good hemodynamic status enter the operating room and undergo anesthesia.In the alpha group (receiving 10mg/kg saline infusion before surgery) before induction of anesthesia, 10mg/kg of normal saline serum will be infused for 5 minutes. Then, the patient will be anesthetized under the supervision of an anesthesiologist. Then, from the onset of surgery to the end of the surgery, 1mg/kg of the same substance will be infused into the serum every hour(for the sake of blinding process). Hemodynamic status and bleeding rate are calculated. Necessary support is induced for the hemodynamic balance of patients. At the same time, drug and placebo infusion continues during surgery. At the end of the surgery, the mentioned items are set up by an anesthesiologist and burn specialist in a questionnaire and the patient is transferred to recovery. In the recovery section, a blood sample is taken to measure the amount of hemoglobin, hematocrit, and coagulation profile.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is no further information is available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>mohammadreza mobayen</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Namjo St, Velayat Hospital</address>
        <city>rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713194</zip>
        <telephone>+98 13 3336 8540</telephone>
        <email>maziar.mobayen@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>mohammadreza mobayen</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Namjoo</address>
        <city>rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713194</zip>
        <telephone>+98 13 3336 8540</telephone>
        <email>maziar.mobayen@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients age between 18 and 50
severe burn (TBSA&gt;20%)
candidate for burn surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>history of cardiovascular disease
Liver or kidney injury
pregnancy or lactating
occular pathologies
different coagulopathies
history of allergy to Tranexamic acid</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>خونریزی از</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>T81.0</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Severe burn patients with good hemodynamic status enter the operating room and undergo anesthesia. In the β group (receiving 10mg/kg tranexamic acid infusion before surgery) before induction of anesthesia, 10mg/kg of tranexamic acid solution in normal saline serum will be infused for 5 minutes. Then, the patient will be anesthetized under the supervision of an anesthesiologist. Then, from the onset of surgery to the end of the surgery, 1mg/kg of the same substance will be infused into the serum every hour. Hemodynamic status and bleeding rate are calculated. Necessary support is induced for the hemodynamic balance of patients. At the same time, drug and placebo infusion continues during surgery. At the end of the surgery, the mentioned items are set up by an anesthesiologist and burn specialist in a questionnaire and the patient is transferred to recovery. In the recovery section, a blood sample is taken to measure the amount of hemoglobin, hematocrit, and coagulation profile.</i_keyword>
      <i_keyword>Control group: Severe burn patients with good hemodynamic status enter the operating room and undergo anesthesia.In the alpha group (receiving 10mg/kg saline infusion before surgery) before induction of anesthesia, 10mg/kg of normal saline serum will be infused for 5 minutes. Then, the patient will be anesthetized under the supervision of an anesthesiologist. Then, from the onset of surgery to the end of the surgery, 1mg/kg of the same substance will be infused into the serum every hour(for the sake of blinding process). Hemodynamic status and bleeding rate are calculated. Necessary support is induced for the hemodynamic balance of patients. At the same time, drug and placebo infusion continues during surgery. At the end of the surgery, the mentioned items are set up by an anesthesiologist and burn specialist in a questionnaire and the patient is transferred to recovery. In the recovery section, a blood sample is taken to measure the amount of hemoglobin, hematocrit, and coagulation profile.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bleeding volume during burn surgery. Timepoint: During surgery. Method of measurement: 1. Blood in the suction machine.2. For each simple surgical gas that is completely impregnated with blood, 20 cc and 40 cc of bleeding will be calculated for each longaze that is completely impregnated with blood.3. The amount of bleeding in the field of surgery: This amount will be expressed according to the estimates of the surgeon and anesthesiologist. In the ninth edition of the Burn Overall Care Book published in 2018, Herndon et al. presented an improved version of the Gross formula first used in 1983, in which the rate of in-operation bleeding is calculated in three main sections. In the first section, the expected blood volume in the patient is calculated. The second section is the fraction of lost blood, which is calculated based on hematocrit before and after surgery. The third section is the amount of volume transferred to the patient during surgery to consider the effects of fluid therapy and its progress effects during surgery on the amount of bleeding. It should be noted that since there is no physician's opinion and the results are expressed subjectively, it will have the lowest bias. Therefore, the main primary outcome in this study is the result of the above formula in CC.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood transfusion. Timepoint: during and in the 24hours of surgery. Method of measurement: packed cells received.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-17</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Burn and Regerenative Medicine Research Center, Poursina four-way, Namjoo Street, Rasht, Guilan Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
